Alterations in lipidome profles distinguish early-onset hyperuricemia, gout, and the efect of urate-lowering treatment
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73622551" target="_blank" >RIV/61989592:15110/23:73622551 - isvavai.cz</a>
Výsledek na webu
<a href="https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-023-03204-6" target="_blank" >https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-023-03204-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13075-023-03204-6" target="_blank" >10.1186/s13075-023-03204-6</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Alterations in lipidome profles distinguish early-onset hyperuricemia, gout, and the efect of urate-lowering treatment
Popis výsledku v původním jazyce
Background : Currently, it is not possible to predict whether patients with hyperuricemia (HUA) will develop gout and how this progression may be afected by urate-lowering treatment (ULT). Our study aimed to evaluate diferences in plasma lipidome between patients with asymptomatic HUA detected≤40 years (HUA≤40) and>40 years, gout patients with disease onset≤40 years (Gout≤40) and>40 years, and normouricemic healthy controls (HC). Methods : Plasma samples were collected from 94 asymptomatic HUA (77% HUA≤40) subjects, 196 gout patients (59% Gout≤40), and 53 HC. A comprehensive targeted lipidomic analysis was performed to semi-quantify 608 lipids in plasma. Univariate and multivariate statistics and advanced visualizations were applied. Results : Both HUA and gout patients showed alterations in lipid profles with the most signifcant upregulation of phosphatidylethanolamines and downregulation of lysophosphatidylcholine plasmalogens/plasmanyls. More profound changes were observed in HUA≤40 and Gout≤40 without ULT. Multivariate statistics diferentiated HUA≤40 and Gout≤40 groups from HC with an overall accuracy of>95%. Conclusion : Alterations in the lipidome of HUA and Gout patients show a signifcant impact on lipid metabolism. The most signifcant glycerophospholipid dysregulation was found in HUA≤40 and Gout≤40 patients, together with a correction of this imbalance with ULT.
Název v anglickém jazyce
Alterations in lipidome profles distinguish early-onset hyperuricemia, gout, and the efect of urate-lowering treatment
Popis výsledku anglicky
Background : Currently, it is not possible to predict whether patients with hyperuricemia (HUA) will develop gout and how this progression may be afected by urate-lowering treatment (ULT). Our study aimed to evaluate diferences in plasma lipidome between patients with asymptomatic HUA detected≤40 years (HUA≤40) and>40 years, gout patients with disease onset≤40 years (Gout≤40) and>40 years, and normouricemic healthy controls (HC). Methods : Plasma samples were collected from 94 asymptomatic HUA (77% HUA≤40) subjects, 196 gout patients (59% Gout≤40), and 53 HC. A comprehensive targeted lipidomic analysis was performed to semi-quantify 608 lipids in plasma. Univariate and multivariate statistics and advanced visualizations were applied. Results : Both HUA and gout patients showed alterations in lipid profles with the most signifcant upregulation of phosphatidylethanolamines and downregulation of lysophosphatidylcholine plasmalogens/plasmanyls. More profound changes were observed in HUA≤40 and Gout≤40 without ULT. Multivariate statistics diferentiated HUA≤40 and Gout≤40 groups from HC with an overall accuracy of>95%. Conclusion : Alterations in the lipidome of HUA and Gout patients show a signifcant impact on lipid metabolism. The most signifcant glycerophospholipid dysregulation was found in HUA≤40 and Gout≤40 patients, together with a correction of this imbalance with ULT.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
10406 - Analytical chemistry
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ARTHRITIS RESEARCH & THERAPY
ISSN
1478-6354
e-ISSN
1478-6362
Svazek periodika
25
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
16
Strana od-do
234
Kód UT WoS článku
001112934800001
EID výsledku v databázi Scopus
2-s2.0-85178341393